



Cohance

Integrated APIs & FDFs:
Science. Scale. Speed.

Cohance at a Glance

34 ⁺	19	15 ⁺	1,000 ⁺
Years of Experience	of Top 20 Innovator Relationships	Years Average Partnership	CDMO Projects Executed
16	200 ⁺	3 billion ⁺	7
CDMO Commercial Molecules	DMFs filed globally across 50+ molecules	OSD manufacturing capacity annually	R&D Centres
500 ⁺	14	8	3500 ⁺ m ³
Scientists	Manufacturing Sites	USFDA / EDQM Accredited Sites	Reactor Capacity



Achieved B-rating 2024 disclosure both in Climate Change & Water Security



Gold in Ecovadis Sustainability Assessment



Targets have been approved by SBTi



97% score in TFS audit



Pharmaceutical Supply Chain Initiative (PSCI) Supplier Partner- 2025



UN Global Compact Commitment for SDG Implementation



UN Global Women Empowerment Program (WEP)



Global Safety Accolade

Our ESG Goals & Aspirations towards shaping a sustainable future

>54 ⁺	>54 ⁺	30%
Reduction in Scope 1, 2 and 3 emissions by 2033	Transition to renewable energy sources by 2033	Reduction in specific water usage through reuse and recycling by 2030
15%	>20%	Net Zero
Reduction in hazardous waste going to landfill by 2033	Women representation in workforce by 2030	GHG emissions by 2050



Integrated Generic API Platform offering solutions across pharma value chain

Cohance's Generic APIs platform offers an integrated approach to serve global customers across high-growth therapeutic areas. Built on a legacy of deep chemistry expertise, we support partners in 60+ countries with reliable, end-to-end solutions.

Why Cohance for Generic APIs

Diverse Portfolio

200+ DMFs filed globally across 50+ molecules

Scale & Reliability

7 cGMP plants with ~1400 KL reactor capacity

Regulatory Strength

15+ successful global regulatory audits in last 2 years

Multi-step Backward Integration

Reliable API supplies enabled by backward integration.

Chemistry at Core

2 R&D centers, 150+ scientists dedicated to generics innovation, handling complex and non-infringing chemistry

Lifecycle Management

Integrated platform capabilities for innovator lifecycle support

Controlled Substances Expertise

Uniquely curated intermediates and APIs portfolio

Integrated FDF Platform

Our FDF division delivers end-to-end solutions — from development to commercialization — helping customers accelerate access to quality medicines worldwide.

Why Cohance for FDFs

Scale & Reliability

3 state-of-the-art facilities, flexible from pilot to commercial scale

Diverse Dosage Coverage

Oral solids, modified release, liquids, semisolids, sachets, topical cloths

R&D Depth

70+ formulation scientists, 40+ commercialized products

Integrated Approach

APIs + FDFs under one roof for faster time-to-market

Global Reach

30+ markets including US, EU, LatAm, Asia, Africa

Regulatory Confidence

USFDA, EU-GMP, WHO-GMP, ANVISA, PMDA, TGA, Health Canada





Global-Accredited Infrastructure



APIs

- 7 cGMP plants | ~1400 KL reactor capacity
- Backward integration for sustainable supply
- 2 R&D centers with 150+ scientists
- **Global accreditations:** USFDA, EDQM, PMDA, ANVISA, Health Canada, TGA
- Delivering complex chemistry with precision, scale & speed

FDFs

- 3 cGMP facilities + 1 dedicated R&D center
- **Capacity Highlights**
 - **Tablets:** 3 Billion+ units annually
 - **Capsules:** 150M+ units
 - **Liquids:** 170 KL
 - **Semisolids & Topicals:** 15 MT
 - **Topical cloths:** 20M units
- **Global approvals:** USFDA, EU-GMP, WHO-GMP, TGA, Health Canada

Generic API+

API Unit-I, Jaggayapet ●
Andhra Pradesh, India

API Unit-II, Atchutapuram ●
Andhra Pradesh, India

API Unit-III, Ankaleshwar ●
Gujarat, India

API R&D Unit-I, Genome Valley ●
Telangana, India

API R&D Unit-II, Ankaleshwar ●
Gujarat, India

FDF Unit-I, Nacharam ●
Telangana, India

FDF Unit-II, Jadcherla ●
Telangana, India

FDF Unit-III, Pashamylaram ●
Telangana, India

FDF Unit-IV, Shamshabad ●
Telangana, India

FDF R&D, Nacharam ●
Telangana, India

● R&D/Early-Stage Manufacturing

● Late-Stage/Commercial Manufacturing

Active Pharma Ingredients - Commercial

Product	USDMF	CEP	EDMF	C-DMF	CA-DIF	KDMF	RUSSIA	ANVISA BRAZIL	Therapeutic Use
Aripiprazole	√	√	√	√		√			Antipsychotic, Antidepressant
Articaine Hcl		√	√			√	√		Anesthetic
Atomoxetine Hcl	√	√	√	√	√		√		ADHD
Baclofen	√	√	√	*		√			Skeletal Muscle Relaxant
Benserazide		√				*			Anti-Parkinson
Betahistine DiHcl		√	√	√	√	*	√	√	Anti-Vertigo
Buspirone	√	*							Anti-anxiety
Calcium Acetate									Phosphate-removing Agent
Cilostazol		**							Antiplatelet
Dabigatran Etexilate Mesylate		*							Anticoagulant
Dapagliflozin Propanediol Monohydrate	√	*	√	*		*		*	Antidiabetic
Desvenlafaxine	√								Antidepressant
Dexmethylphenidate Hcl									ADHD
Diffunisal	√		√	√					NSAID
Dipyridamole	√	√			√		√		Antiplatelet
Doxazosin Mesylate	√	√	√		√		√	*	Antihypertensive
Drotaverine Hcl			√	√			√		Antispasmodic
Entacapone	√	√	√	√	√	√	√	√	Anti-Parkinson
Fenoprofen	√								NSAID
Flurbiprofen		√	√			√	*		NSAID
Fluvoxamine Maleate	√	√	√	√			√	*	Antidepressant
Glycopyrrolate	√								Anticholinergic Agent
Hydralazine Hcl	√								Antihypertensive
Hydroxyzine Pamoate	**								Antihistamine
Irinotecan HCl Trihydrate		√							Oncology
Isosulfan Blue	√								Diagnostic Dye
L-Carglumic Acid									Ammonia Detoxicants
Lamotrigine	√	√	√	√	√	√	√	√	Antiepileptic
Levodropropizine		√							Antitussive, Cough suppressant
Levomepromazine Maleate		√							Antipsychotic
Lercanidipine		*							Antihypertensive
Lisdexamfetamine dimesylate								*	ADHD
Lurasidone Hcl	√								Antipsychotic

√ Available / Approved

* Filed / Awaiting Approval

** To be Filed

Active Pharma Ingredients - Commercial

Product	USDMF	CEP	EDMF	C-DMF	CA-DIF	KDMF	RUSSIA	ANVISA BRAZIL	Therapeutic Use
Malathion									Cholinesterase Inhibitors
Maraviroc	√								Antiretroviral
Mebeverine HCl		√	√	√			√	*	Antispasmodic
Methylene Blue									Oxidation- Reduction Agent
Methylphenidate Hcl		√		*	√			*	ADHD
Metyrosine	√				*				Catecholamine Synthesis Inhibitor
Mexiletine Hcl	√								Antiarrhythmia
Midazolam	√	√	√		*	√		√	Anesthetic
Mirabegron	√			√		*			Adrenergic Agonists
Nitazoxanide	√								Anti-Infective
Oxolamine Citrate									Cough suppressant
Oxolamine Phosphate									Cough suppressant
Oxymetazoline		*							Decongestant, Vasoconstrictor
Pinavarium bromide	**								Antispasmodic
Pirfenidone	√	√		√	√	√			AntiInflammatory, Antifibrotic
Posaconazole	√		√						Antifungal
Probenecid	√								Uricosuric Agents
Pyridosigmine		**							Cholenesterase inhibitor
Quetiapine Fumarate	√	√		√	√	√	√	√	Antipsychotic
Ractopamine Hcl	√				√			*	Animal Feed Additive
Rivaroxaban	√	√	√	√	√	*	√	*	Anticoagulant
Sulfasalazine	**								Anti-Inflammatory
Tamsulosin Hcl	√	√	√	√	√		√	*	Benign Prostatic Hyperplasia
Tapentadol Phosphate			√						Anesthetic
Trientine	√								Copper Chelating Agent
Trimebutine maleate		*							Antispasmodic
Trimetazidine dihydrochloride		*							Antianginal
Venlafaxine Hcl	√	√	√	√	√				Antidepressant
Zilpaterol									Veterinary
Zonisamide	√		√	√		√			Anticonvulsant

√ Available / Approved

* Filed / Awaiting Approval

** To be Filed

Disclaimer: All transactions are carried out in accordance with the patent laws applicable in the user's country. Responsibility for third-party patent rights in a specific country lies exclusively with the buyer. The therapeutic uses listed for each product are indicative only and are not intended to advertise Cohance/ZCL/Avra products. Patented products are available for R&D use as permitted under 35 USC 271(e)(1).

Active Pharma Ingredients - Under Development

Product	Therapeutic Use	Development Status
Apixaban	Anticoagulant	Lab Optimization
Acotiamide	Anti-Dyspepsia	Proof of Concept
Dexlansoprazole	Proton Pump Inhibitors	Proof of Concept
Edoxaban	Anticoagulant	Lab Validation
Erdosteine	Mucolytic Agent	Proof of Concept
Hydroxyzine Pamoate	Antihistamine	Under Development
Indapamide	Antihypertensive	Proof of Concept
Lercanidipine	Antidepressant, Anxiolytic	Under Validation
Loxoprofen	Non-Steroidal Anti-Inflammatory	Validation Completed
Nintedanib Esylate	AntiInflammatory, Antifibrotic	Proof of Concept
Propafenone	Antiarrhythmic agents	Lab Validation
Pyridostigmine Bromide	Cholinesterase inhibitor	Under Development
Psilocybin Intermediate	Antipsychotic	Under Development
Remimazolam Besylate	Sedative, General Anesthetic	Under Validation
Safinamide	Anti-Parkinson	Lab Optimization



Intermediates			
Product	Plant Validation	Current Status	CAS No.
3 -Amino-Piperidine-2,6-Dione HCl	Lenalidomide	Commercial	24666-56-6
3-Nitro-2- Bromomethyl Methyl Benzoate	Lenalidomide	Commercial	98475-07-1
2'-Amino-5'-hydroxypropiophenone (AHP)	Irinotecan	Commercial	35364-15-9
N-(4-(methylamino)benzoyl)-l-glutamic acid diethyl ester	Methotrexate	Commercial	2378-95-2

Intermediates List		
Product	CAS No.	API
Phenyl-(2-pyridyl acetamide)	7251-52-7	Methylphenidate
Phenyl-2-(2'-piperidyl) acetamide	19395-39-2	Methylphenidate
threo-phenyl-2-piperidyl acetamide	50288-62-5	Methylphenidate
dl-threo-Ritalinic acid	54631-24-2	Methylphenidate
(2R)-phenyl[(2R)-piperidin-2-yl]ethanoic acid hydrochloride	741705-70-4	Dexmethylphenidate
(S)-tert-butyl 3-(tert-butoxy)-2-(nicotinamido)propanoate (R)-chloromethyl 2-((R)-2-methoxy-2-oxo-1-phenylethyl)piperidine-1-carboxylate	2229891-12-5 2229891-13-6	Serdexmethylphenidate
Tert-butyl N-[(2S)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-1-oxo-1-[[[(2S)-1-phenylpropan-2-yl]amino]hexan-2-yl]carbamate (Lisdexamfetamine Intermediate (LDX-I))	819871-13-1	Lisdexamfetamine dimesylate
2-aminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1h-1,4-benzodiazepine dimaleate	59469-29-3	Midazolam
2-[(2S)-oxiran-2-ylmethyl]-1H-isoindole-1,3(2H)-dione	161596-47-0	Rivaroxaban
5-chlorothiophene-2-carboxylic acid	24065-33-6	Rivaroxaban
(2S, 3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol	809282-20-0	Tapentadol
3-Methoxy propiophenone	37951-49-8	Tapentadol
3-Hydroxy propiophenone	13103-80-5	Tapentadol
2-(2,3-Dichlorophenyl)-2-(guanidinylimino)acetonitrile (Schiff Base)	84689-20-3	Lamotrigine
Methyl Olivetolate	58016-28-7	Cannabidiol
Olivetol	500-66-3	Cannabidiol
Menthadienol (MTH)	22972-51-6	Cannabidiol
4-Amino-2-chloro-6,7-dimethoxyquinazoline	23680-84-4	Doxazosin Mesylate
Methyl 3-((3S)-7-bromo-2-((2-hydroxypropyl)amino)-5-(pyridin-2-yl)-3H-benzo[e][1,4] diazepin-3-yl)propanoate (REM-II)	308243-54-1	Remimazolam Besylate
(S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamido)-3-phenylpropanoic acid	868540-16-3	Carfilzomib
(S)-2-amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one trifluoroacetic acid salt	247068-85-5	Carfilzomib
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone	461432-22-4	Dapagliflozin and Ertugliflozin
5-Bromo-2-chloro-4'-ethoxydiphenylmethane	461432-23-5	Dapagliflozin and Ertugliflozin
(S)-8-Ethyl-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-aza-cyclopenta [b] naphthalene-1,4,7-trione	110351-94-5	Irinotecan
2'-Amino-5'-hydroxypropiophenone	35364-15-9	Irinotecan
7-Ethyl-10-hydroxycamptothecin (SN-38)	86639-52-3	Irinotecan
10-Hydroxycamptothecin	19685-09-07	Topotecan
4-Fluoro-2-methoxy-5-nitroaniline	1075705-01-9	Osimertinib
N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine	1421372-94-2	Osimertinib

Preformulation Intermediates (Pellets)										
Product	DMF/ Techpack	Bioequivalence Established	Type of BE Study	RLD/ Market	Stability	Brazil	Turkey	Mexico	MENA	APAC
Duloxetine HCl Delayed Release Pellets 20% (HPMC Acetyl Succinate)	DMF	Yes	Fast & Fed	CYMBALTA / EU	Available -36 M	Yes	Yes	Yes	Yes	Yes
Duloxetine HCl Delayed Release Pellets 20% (HPMC Phthalate)	DMF/ Techpack	Yes	Fasting & Fed	CYMBALTA/ Turkey/EU	Available -36 M	No	No	No	No	Yes
Duloxetine Delayed Release Pellets 17% (HPMC Phthalate)	DMF/ Techpack	No	No	-	Available - 12 M	Yes	No	No	Yes	Yes
Itraconazole Immediate Release Pellets 21.74%	DMF	Yes	Fasting & Fed	SPORANOX/ US	Available -36 M	No	No	Yes	No	Yes
Itraconazole Immediate Release Pellets 22%	DMF	No	No	-	Available -36 M	Yes	No	Yes	Yes	Yes
Venlafaxine HCl Extended Release Pellets 33%	Dossier/ DMF	Yes	Fasting & Fed	EFFEXOR /EU	Available -36 M	Yes	Yes	Yes	Yes	Yes
Omeprazole Delayed Release Pellets 8.5% (LD-30)	Dossier/ DMF	No		No	Available -36 M	No	No	Yes	Yes	Yes
Omeprazole Delayed Release Pellets 8.5% (Phthalate)	Dossier/ DMF	Yes	Fast & Fed	Customer Established BE in Indonesia	Available -36 M	No	No	Yes	Yes	Yes
Tamsulosin Modified Release Pellets 0.12%	Dossier	Yes	Fasting & Fed	FLOMAX/US, SANDOZ/ CANADA	Available - 6 M	No	No	No	Yes	No
Tamsulosin HCl Modified Release Pellets 0.2%	DMF	No	No	FLOMAX/US	Available -36 M	Yes	Yes	Yes	Yes	Yes
Mebeverine HCl Sustained Release Pellets 80%	DMF	Yes	Fast & Fed & MDD/ SS	Colofac Retard 200 mg/EU	Available -36 M	Yes	Yes	No	Yes	Yes
Fenofibrate Sustained Release Pellets 75%	DMF	No	No	No	Available -36 M	Yes	No	No	Yes	No
Orlistat Immediate Release Pellets 50% (Extrudes)	DMF	No	No	Xenical / EU	Available -36 M	Yes	No	Yes	Yes	Yes
Lansoprazole Delayed Release Pellets 8.5%	DMF	Yes	Fast & Fed	AGOPTON/ EU	Available -36 M	Yes	Yes	Yes	Yes	Yes
Methylphenidate HCl Extended Release Pellets 11%	DMF/ Techpack	Yes	Fast & Fed	RITALIN LA/ BR	Available -12 M	Yes	No	No	No	No
Methylphenidate HCl Immediate Release Pellets 11%	DMF/ Techpack	Yes	Fast & Fed	RITALIN LA/ BR	Available -12 M	Yes	No	No	No	No

Preformulation Intermediates - Under Development

Under development	DMF/ Techpark	Bioequivalence Established	Type of BE Study	RLD/ Market	Stability	Brazil	Turkey	Mexico	MENA	APAC
Duloxetine Hydrochloride Delayed Release Pellets 16%	Techpack	No	No	No	Available 6 M	-	-	-	-	-
Trimetazidine Extended Release Pellets 55%	Techpack	No	No	VASTAREL MR/ Brazil	Available 3 M	Yes	-	-	-	-
Dabigatran Etexilate Pellets 35%	Techpack	No	Fast Single Dose Study	PRADAXA/ US	Available	-	-	-	Yes	-
Dabigatran Etexilate Mesylate Pellets 40%	Techpack	No		No	Available	-	-	-	-	Yes





Collaborate.
Enhance.
Deliver.

